secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001551152-24-000013
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie updates 2024 EPS guidance after incurring $164M IPR&D expense in Q1
--------------------------------------------------------------------------

- Acquired IPR&D and milestones expense of $164M pre-tax ($0.08 per share) recorded in Q1 2024.
- Q1 2024 adjusted diluted EPS guidance revised to $2.18-$2.22 from $2.26-$2.30 previously.
- Full-year 2024 adjusted diluted EPS guidance revised to $10.97-$11.17 from $11.05-$11.25.
- Future IPR&D and milestones expense excluded from guidance due to unpredictable deal timing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000013/0001551152-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000013/abbv-20240403.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer